ReviewThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2020
Emerging Use of Epidiolex (Cannabidiol) in Epilepsy.
Review in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05324449 (Epidiolex® For The Treatment Of Anxiety Comorbidity in Refractory Pediatric Epilepsy), which is not on this map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Epidiolex® For The Treatment Of Anxiety Comorbidity in Refractory Pediatric Epilepsy
Who cites it
59 citing papers in PubMed, 106 citations in OpenAlex.
- Industrial Hemp and Tobacco as Multipurpose Crops: Traditional Uses, Contemporary Applications, and Future Perspectives.Plants (Basel, Switzerland) · 2026Review
- Metabolomic diversity and spatial localization of bioactive compounds in hemp achenes from diverse landraces.Journal of pharmaceutical analysis · 2026Article
- Article
- Unveiling the role of CB2 receptor in beta-hydroxybutyrate mediated modulation of.Journal of physiology and biochemistry · 2026Article
- High-Throughput LC-MS/MS Quantification of Eighteen Cannabinoids in Hemp Flowers with Baseline Separation of Structural Isomers.Molecules (Basel, Switzerland) · 2026Article
- Cannabinoids and drug-drug pharmacokinetic interactions: Deciphering the risks.British journal of clinical pharmacology · 2026Review
- Assessing patient perceptions of off-label cannabidiol use for insomnia through sentiment analysis.Journal of cannabis research · 2025Article
- Cannabinoids rescue migraine symptoms caused by central CGRP administration in mice.Cephalalgia : an international journal of headache · 2025Article
- Cannabidiol Loaded Nanoemulsion with Improved Bioaccessibility and Anti-Inflammatory Activity.ACS omega · 2025Article
- Influence of Different Amino Acids on the Aerosolization, Stability and Cytotoxicity of Spray-Dried Cannabidiol Dry Powder for Inhalation.Pharmaceutics · 2025Article
- Recent Preclinical Evidence on Phytocannabinoids in Neurodegenerative Disorders: A Focus on Parkinson's and Alzheimer's Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Multiple intramolecular triggers converge to preferential G protein coupling in the CBNature communications · 2025Article
- Article
- Beyond the hype: a comprehensive exploration of CBD's biological impacts and mechanisms of action.Journal of cannabis research · 2025Review
- Towards Enhanced Solubility of Cannabidiol: Preparation and Evaluation of Cannabidiol Solid Dispersions Using Vacuum Compression Molding.AAPS PharmSciTech · 2025Article
- Mechanisms ofMicroorganisms · 2025Article
- A novel insight into the antidepressant effect of cannabidiol: possible involvement of the 5-HT1A, CB1, GPR55, and PPARγ receptors.The international journal of neuropsychopharmacology · 2025Review
- Microencapsulation techniques for developing cannabidiol formulations: a review.Therapeutic delivery · 2025Review
- Development and Blood-Brain Barrier Penetration of Nanovesicles Loaded with Cannabidiol.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Update on Cannabidiol in Drug-Resistant Epilepsy.Indian journal of pediatrics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first plant-derived, purified pharmaceutical-grade cannabidiol (CBD) medication, Epidiolex, was approved in the United States by the FDA on June 25, 2018. Its approval for patients ≥ 2 years of age with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS) markedly altered the treatment of medically refractory seizures in these disorders. This state-of-the-art review will discuss the history of CBD, its current pharmacology and toxicology, evidence supporting its use in a variety of epileptic syndromes, common side effects and adverse effects, and pharmacokinetically based drug-drug interactions. Owing to the importance in considering side effects, adverse effects, and drug-drug interactions in patients with medically refractory epilepsy syndromes, this review will take a deeper look into the nuances of the above within a clinical context, as compared to the other antiepileptic medications. Furthermore, despite the limited data regarding clinically significant drug-drug interactions, potential pharmacokinetic drug-drug interactions with CBD and other antiepileptics are theorized on the basis of their metabolic pathways. The article will further elucidate future research in terms of long-term efficacy, safety, and drug interactions that is critical to addressing unanswered questions relevant to clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.